CN Bio logoCN Bio logoCN Bio logoCN Bio logo
  • Products
    • Explore our solutions


      PhysioMimix™ products enable you to recreate complex human biology and accurately predict human drug responses

      PhysioMimix OOC

      PhysioMimix OOC systems
      Learn more

      Consumables

      • Multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
      Learn more

      Models

      • Single-organ models
      • Multi-organ models

      Support packages

      • PhysioMimix™ support packages
  • Applications
    • Discover the applications


      Investigate the application areas that our PhysioMimix™ products and services support

      Learn more

      Disease modeling

      • Non-Alcoholic Steatohepatitis
      • Hepatitis B
      • Oncology
      • COVID-19
      Learn more

      Safety toxicology

      • Drug-induced liver injury
      • Immune-mediated toxicities
      Learn more

      ADME

      • Drug absorption
      • Drug metabolism
      • Drug bioavailability
      Learn more
  • Services
    • Studies as a service


      Our team will work collaboratively with you to design a study around your research goals and generate actionable data within weeks

      Learn more
      NAFLD / NASH icons

      NAFLD / NASH

      Drug-induced liver injury icon

      Drug-induced liver injury

      icon adme |

      ADME

      Oncology icon

      Oncology

  • Resources
  • Company
    • About us


      Meet the team, explore our culture and discover what to expect when working with us

      CN Bio team photo
      About us

      Latest news

      • The FDA further expands collaboration with CN Bio to evaluate the PhysioMimix Multi-organ microphysiological system

      • The U.S. FDA Modernization Act 2.0. Now the animal testing mandate is removed, learn what can be embraced in its place.

      • CN Bio appoints Dr Paul Brooks as Chief Executive Officer

      View all news

      Upcoming Events

      • SLAS2023

      • SOT 2023

      • WORD 2023

      • SLAS Europe 2023

      • MPS World Summit 2023

      View all events

      Join the team!

      View all jobs
  • Contact
  • Products
    • PhysioMimix™ OOC Microphysiological Systems
    • Consumables
      • PhysioMimix™ multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
    • Organ-on-a-chip models
    • Support packages
  • Applications
    • Disease modeling
    • Safety toxicology
    • ADME
  • Services
    • Non-Alcoholic Steatohepatitis
    • Drug-Induced Liver Injury
    • ADME
  • Resources
  • Company
    • About us
    • Events
    • News
    • Careers
  • Contact
  • Skip to main content
  • Skip to footer
Chat live with an expert

Organ-on-a-Chip Resources

Resource type

Area of interest

Scientific publications

Resource image

Normalization of organ-on-a-Chip samples for mass spectrometry based proteomics and metabolomics via Dansylation-based assay

Gallagher et al., 2022

This study shows the importance of normalization for paired MS-based multi-omics-OOC studies to accurately investigate highly toxic hazards and their effects on the human liver. Using VX, a highly toxic chemical compound, the study identifies VX-specific toxic effects on 3D liver tissues as well as specific hepatic cellular biomarkers and pathways affected by the toxic agent.

Application notes

Resource image

Human liver microphysiological system for predicting the drug-induced liver toxicity of differing drug modalities

Novac et al

The liver is one of the organs most susceptible to drug toxicity and drug-induced liver injury (DILI). With more than 750 FDA-approved drugs known to have a degree of DILI risk, better preclinical models are required to de-risk new therapeutics earlier in the drug development process.​ We assess whether a Liver MPS model could be used to understand the detailed mechanistic aspects of liver toxicity.

Application notes

Resource image

Microphysiological system for studying fatty liver disease and its impact on drug-induced liver injury

Kostrzewski et al

As a result of the increased prevalence of diabetes, obesity, and metabolic syndrome, non-alcoholic fatty liver disease (NAFLD) is now the most common chronic liver disease in developed countries. Using better in vitro models to fast-track therapeutic development but also accurately assess DILI risk in NASH patients ahead of the clinic is critical. Here, we show the potential of an in vitro 3D NASH model to accurately identify any DILI-associated risks.

Posters

Resource image

Assessing drug-induced liver injury using a sensitive and selective human liver microphysiological system and clinical biomarkers

Novac et al

Drug-induced liver injury (DILI) is the most common cause of acute liver failure and a leading cause of compound attrition in drug development. In this poster, we demonstrate the potential of a liver MPS to better predict toxicity and improve in vitro to in vivo translation.

Scientific publications

Resource image

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Novac et al., 2022

This study demonstrates the capability of a human liver MPS to generate clinically-relevant, high-content data (six endpoint EC50 curves). A broad set of known severely and mildly hepatotoxic compounds to accurately predict human DILI and its mechanism versus conventional approaches.

Scientific publications

Resource image

Multiorgan microphysiological systems as tools to interrogate interorgan crosstalk and complex diseases

Trapecar, 2022

A review of the state of multi-organ microphysiological systems in 2021. Overviews of currently available multi-organ MPS and the different technologies, cells and physiological cues used. Discusses approaches for systems biology integration and how MPS can be more readily adopted in the wider research community.

Blogs

Resource image

De-risking drug-induced liver injury through the predictive power of organ-on-a-chip

Unfortunately, it is not uncommon that DILI (Drug-induced liver injury) is only first identified in the clinic. Find out how our systems can help you identify it in your lab.

Webinars

Resource image

Fighting Toxic Chemicals: Evaluating the Safety of Cobinamide as a Neutralizing Agent

Webinar Series 4 Episode 3:

This webinar outlines how Boss’ lab used CN Bio’s DILI Services to investigate the hepatotoxicity of two cobinamide formulations.

Webinars

Resource image

Predictive DILI Models: Human Liver Microphysiological System for Studying Acute and Chronic Drug-Induced Liver Toxicity

Webinar Series 4 Episode 2:

In this webinar, CN Bio Senior Scientist Dr. Ovidiu Novac discusses how a human liver microphysiological system (MPS), or Liver-on-a-chip, can be used to understand the causality and mechanistic aspects of drug-induced liver injury (DILI).

Scientific publications

Resource image

Characterizing the reproducibility in using a liver microphysiological system for assaying drug toxicity, metabolism and accumulation

Rubiano et al., 2020

This study demonstrated the ability of the CN Bio’s PhysioMimix liver model to generate reproducible results from experiments assaying metabolism, drug toxicity and intracellular accumulation. The results from the paper showed that the liver MPS can be routinely used in general drug evaluation applications.

Videos and animations

Resource image

Predicting the future: humanised drug evaluation testing using organ-on-a-chip technology

CN Bio’s mission is to transform drug discovery through the development of disruptive single and multi-organ microphysiological systems (MPS) -otherwise known as organ-on-a-chip – that optimize the accuracy and efficiency of bringing new medicines to market.

Scientific publications

Resource image

Interconnected microphysiological systems for quantitative biology and phamarcology studies

Edington et al., 2018

A proof-of-principle study that demonstrates microphysiological systems are capable of modeling multiple organs enabling pharmacological testing of drugs and assessing organ-organ cross-talk, this was done through measuring functional biomarkers for the liver and brain and TEER for the gut and lungs over time.

Speak to our experts

Speak directly with one of our OOC experts to see how our products and services can support your studies

Request a meeting

Footer

CN Bio logo

332 Cambridge Science Park, Milton Road
Cambridge, CB4 0WN

+44 (0) 1223 737941

Privacy | Cookies | Terms | Regulatory | Accessibility

©2023 CN Bio Innovations Ltd
Registered No. ‍06517359. VAT No. 978184563

Latest news

  • The FDA further expands collaboration with CN Bio to evaluate the PhysioMimix Multi-organ microphysiological system January 17, 2023
  • The U.S. FDA Modernization Act 2.0. Now the animal testing mandate is removed, learn what can be embraced in its place. January 9, 2023
  • CN Bio appoints Dr Paul Brooks as Chief Executive Officer December 19, 2022

Upcoming events

MPS World Summit 2023 June 26-30, 2023

SLAS Europe 2023 May 22-26, 2023

SLAS2023 February 25 - March 1, 2023